European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma
Pier Luigi Zinzani(Istituto di Ematologia di Bologna), F. Morschhauser(Université de Lille), Martine E.D. Chamuleau(Hovon), John Radford(Manchester Academic Health Science Centre), Tony Ng(King's College London), Lionel Karlin(Hôpital Lyon Sud), Corinne Haïoun(Assistance Publique – Hôpitaux de Paris), Catherine Thiéblemont(Université Paris Cité), Eva González‐Barca(Institut Català d'Oncologia), Karen M. Dwyer(The Royal Melbourne Hospital), Coralith García(Hospital Universitario 12 De Octubre), Paul Fields(Guy's Hospital), Gustaaf W. van Imhoff, Peter Johnson(Cancer Research UK), Dolores Caballero(Complejo Hospitalario de Salamanca), Francesco d’Amore(Aarhus University)
Cited by 48
Related Papers
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
|The Journal of Experimental Medicine|2007|2.4k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
|The Journal of Experimental Medicine|2003|1.1k
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy
|European Journal of Cancer|1993|545